The subject of gene patentability is one of the most controversial topics in life sciences. In June 2013, the US Supreme Court reached a unanimous decision in the Association for Molecular Pathology v Myriad Genetics. It stated that companies cannot patent parts of naturally occurring human genes. Managing IP sat down with Fitzpatrick Cella Harper & Scinto attorneys Robert Fischer, John Carlin and Joshua Rothman to discuss the ruling
Unlock this content.
The content you are trying to view is exclusive to our subscribers.
MBIP principals Andy Mukherji and Ellen Reid discuss the firm’s combination with Jones Tulloch and reveal why younger firms stand to gain from AI demand
Managing IP will help mark IP Inclusive’s 10th anniversary by co-hosting a new podcast series covering diversity, equity, and inclusion within the IP profession
Bradford Newman, who has joined the firm’s new Silicon Valley office as head of complex technology disputes, discusses plans to build the practice group and attract local talent